There are a few important heart failure guideline updates in the works to the American College of Cardiology’s Heart Failure Guidelines, last published in 2013. Prior to the full guideline release, the organization recently printed their updated Expert Consensus...
SGLT2s like empagliflozin, dapagliflozin, ertugliflozin, and canagliflozin are getting more use in diabetes care as time goes on. As a geriatric pharmacist, I certainly recognize that these agents have a lot of potential benefits, but they can also have adverse...
Sodium-glucose co-transporter 2 inhibitors (SGLT2s) are becoming popular treatments for type 2 diabetes mellitus. While typically classified as diabetes medications, there is more and more research coming out for their benefits in cardiovascular health and heart...
A compelling indication is simply another reason (typically a disease state) as to why you choose a medication. Compelling indications in diabetes are increasingly important in medication selection in diabetes. I lay out some of those reasons below. Metformin...
Orthostasis risk with SGLT-2 Inhibitors is a potential minor concern, particularly in our geriatric population. While a drop in blood pressure can be a good thing for a significant chunk of diabetes patients, that potential modest drop can lead to an increased...
